Mark Cuban’s generic-drug play isn’t just another healthcare “disruption” story—it’s a stress test for an industry that has grown comfortable with delay, complexity, and delay-as-a-business-model.
Here’s the hook: when generics move faster than incumbe…

Biotech hiring isn’t just a labor market story—it’s a patent story.
When you see a spike in job postings for “business development,” “licensing,” “IP strategy,” or “deal execution,” it often signals something more specific than growth for growth’s sake…

Patent cliffs aren’t just a legal event. They’re a pricing strategy.
Pharma has a way of turning “end of exclusivity” into “new beginning”—and the playbook is getting more sophisticated.
In a world where investors expect revenue to fall off a cliff the…

Drug pricing transparency is having a moment. Policymakers, payers, and patient advocates increasingly argue that if we just shine a brighter light on how medicines are priced—rebates, discounts, net prices, contracting terms—costs will fall and access…

Big Pharma isn’t the only player in the drug pricing game anymore—and if you’re modeling risk in healthcare, you need to update your assumptions.
Mark Cuban’s “cost-plus” approach has sparked a strategic debate that goes far beyond politics or branding…

Pharma doesn’t “miss” patent dates. It just doesn’t miss them publicly.
Behind every headline about a blockbuster’s next extension window is a quieter, more technical story: how companies track IND and NDA timelines across jurisdictions to position pat…

Pharma doesn’t just file patents—it runs a global calendar.
In the race to extend exclusivity, the winners aren’t always the companies with the biggest R&D budgets. They’re the ones with the tightest operational intelligence: the ability to track I…

Generic drug competition is supposed to be simple: file, prove sameness, win approval, launch. But anyone who’s tried to navigate complex generics knows the real story is messier—especially when the product isn’t a straightforward “copy” and the regula…

Pharma’s biggest talent risk isn’t hiring—it’s timing.
Most companies build their teams the same way: wait for a vacancy, post a role, interview candidates who are already “on the market.” But in patent strategy, that approach is often a half-step behi…